InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-22.1%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Whiting Samuel, Directeur Médical. Director active across 2 companies, notably Millendo Therapeutics, Inc.. Cumulatively, 5 disclosures have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €24k. History available since 6 January 2022. The latest transaction was filed on 2 July 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations5 total
4,672 shares@ US$2.1339.1% of flowCommon StockSEC:0001415889-24-019279:0
Ideal exit: 29 Mar 2025 (T+270)
1,700 shares@ US$4.80480.027% mcap50.0% of flowCommon StockSEC:0001209191-22-002753:0
Ideal exit: 3 Oct 2022 (T+270)
1,700 shares@ US$4.804830.5% of flowCommon StockSEC:0001209191-22-002753
Ideal exit: 3 Oct 2022 (T+270)
201 sharesCommon StockSEC:0001140361-21-022931
201 sharesCommon StockSEC:0001140361-21-022931:0
5 of 5 declarations
About Whiting Samuel
Whiting Samuel is the Chief Medical Officer at Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. In this role, he is responsible for the medical strategy and research initiatives of the companies. His expertise in the medical field allows him to lead innovative projects aimed at improving treatments for patients. He plays a key role in the development of new therapies.
